pCBh-NLS_hfCas13d(RfxCas13d_N2V8)_HA_NLS-pA-U6-DR-BpiI-BpiI-pSV40-EGFP-pA-pSV40-mCherry-pA Citations (2)

Originally described in: High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
Tong H, Huang J, Xiao Q, He B, Dong X, Liu Y, Yang X, Han D, Wang Z, Wang X, Ying W, Zhang R, Wei Y, Xu C, Zhou Y, Li Y, Cai M, Wang Q, Xue M, Li G, Fang K, Zhang H, Yang H Nat Biotechnol. 2022 Aug 11. pii: 10.1038/s41587-022-01419-7. doi: 10.1038/s41587-022-01419-7. PubMed Journal

---

Articles Citing pCBh-NLS_hfCas13d(RfxCas13d_N2V8)_HA_NLS-pA-U6-DR-BpiI-BpiI-pSV40-EGFP-pA-pSV40-mCherry-pA

Articles
Programmable RNA writing with trans-splicing. Schmitt-Ulms C, Kayabolen A, Manero-Carranza M, Zhou N, Donnelly K, Nuccio SP, Kato K, Nishimasu H, Gootenberg JS, Abudayyeh OO. bioRxiv [Preprint]. 2024 Feb 1:2024.01.31.578223. doi: 10.1101/2024.01.31.578223. PubMed
Targeted PLK1 suppression through RNA interference mediated by high-fidelity Cas13d mitigates osteosarcoma progression via TGF-beta/Smad3 signalling. Yuan Y, Cao D, Zhang A, Liu Z, Deng Z, Zhang S. J Cell Mol Med. 2024 May;28(10):e18400. doi: 10.1111/jcmm.18400. PubMed

If you have published an article using this material, please email us at to have your article added to this page.